Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japanese drug developer Daiichi Sankyo has received the US Food and Drug Administration (FDA) approval for the supplemental new drug application (sNDA) of Welchol (colesevelam HCl) for Oral Suspension.
Subscribe to our email newsletter
Welchol for Oral Suspension is used in comination with fruit juice or diet soft drinks, and is indicated for the adult patients suffering from primary hyperlipidemia and type 2 diabetes.
Daiichi Sankyo‘s Welchol helps in improving LDL cholesterol and glycemic control when used in addition with diet and exercise by the adult patients with high LDL cholesterol and type 2 diabetes.
Daiichi Sankyo Medical Research and Strategy Therapeutic Areas Hypertension and Metabolism head, executive medical director Oliseyenum Nwose said Welchol for Oral Suspension is once-daily, sugar-free, citrus-flavored and non-systemically absorbed, which means it is not metabolized in the liver or kidneys.